Belief BioMed Completed Dosing of the First Subject in the R

Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B

/PRNewswire/ -- On December 30th, 2021, Belief BioMed Group (BBM) announced that it has successfully dosed the first subject in the registrational gene therapy...

Related Keywords

China , Shanghai , Xiao , Belief Biomed Group , Belief Biomed , Chief Science Officer , Investigator Initiated Trial , Belief Biomed Inc ,